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Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most targeted pro-
teins in breast cancer’s therapy. There is no globally accepted method for determining its status. Here, we aimed to
evaluate the immunohistochemistry method validity in predicting HER-2 status by Fluorescence in situ hybridization
method and investigate some clinicopathological variables association with HER-2 ampliﬁcation. A total of 190 HER-2
2+ and 3+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. Fluorescence in situ
hybridization (FISH) was performed for these cases using FDA criteria and the association between clinicopathological
variables and HER-2 status evaluated. Study consisted of 190 invasive breast cancer patients (160 HER-2 2+ and 30
HER-2 3+). HER-2 FISH ampliﬁcation according to FDA criteria was found 27.5% (44/160 patients) in HER-2 2+
patients and 83.3% (25/30 patients) in HER-2 3+ patients. Tumors with HER-2 ampliﬁcation were more likely to be
ER-negative (51.0% vs 31.2%, p = 0.013) and PR-negative (52.9% vs 27.0%, p < 0.001). This study showed that
immunohistochemistry is not a good method for evaluating HER-2 status and decision-making about trastuzumab ther-
apy even with 3+ score patients. However, this result may not be too strong for IHC 3+ cases due to the limited num-
ber of these patients in this study.
Key words: Invasive breast cancer; human epidermal growth factor receptor-2; immunohistochemistry; ﬂuorescent
in situ hybridization; prediction.
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Breast cancer is responsible for 28% of the newly
diagnosed cancer cases in women worldwide and
second leading cause of cancer death in human (1,
2). Breast cancer with HER-2 overexpression cur-
rently comprises 15–20% of all cases in the world
(3). HER-2/neu, located on chromosome 17q21,
encodes for the 185-kD transmembrane glycopro-
tein HER-2CA, which is one of the most targeted
proteins and plays a role in cell growth, diﬀerentia-
tion, adhesion, motility, and signal conduction (4).
HER-2 ampliﬁcation or overexpression has been
demonstrated to be an independent parameter for
bad prognosis. Even adjuvant hormonal therapy is
not suﬃcient for these patients with positive estro-
gen receptors (5, 6).
HER-2-targeted therapies have signiﬁcantly
improved disease-free survival in women withReceived 6 December 2015. Accepted 21 December 2015
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HER-2-positive cancers both in early and meta-
static breast cancer (7, 8). Three HER-2-targeted
agents, trastuzumab (Herceptin), lapatinib
(Tykerb), and pertuzumab (Perjeta), have been
made available in the past decade for the treatment
of HER-2-positive metastatic breast cancer (9). The
importance of precise detection of HER-2 ampliﬁ-
cation is cleared with knowing the diﬃculties
imposed by a 1-year course of treatment with Her-
ceptin; this drug carries a substantial ﬁnancial bur-
den and perhaps, more importantly, introduces the
risk of cardiotoxicity (10–12).
The US Food and Drug Administration (FDA)
approved methodologies include the assessment of
the protein level by immunohistochemistry (IHC)
or gene copy count on the DNA level by in situ
hybridization technology (ISH) (13, 14). Fluores-
cence in situ hybridization (FISH) is considered the
gold standard for evaluating HER-2 status, which
has become essential in the era of personalized can-
cer therapy (13, 15). IHC is the most frequently
used as initial laboratory test for HER-2 protein
expression, because it is convenient and inexpen-
sive. HER-2 IHC results are generally divided into
four scale scores (range, 0–3+) on the basis of per-
centage of positive tumor cells and staining inten-
sity. The US Food and Drug Administration
(FDA) and American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAPs)
recommends that HER-2 IHC scores of 0 and 1+
should be regarded as HER-2 negative and those
with HER-2 3+ scores should be considered HER-2
positive. Tumors that show strong circumferential
staining in <10% of tumor cells or incomplete and/
or weak/moderate staining of >10% of the invasive
tumor cells are categorized IHC 2+ score and are
regarded as HER-2 equivocal and should be further
assessed by FISH (16, 17).
The aims of the study were to evaluate the accu-
racy of immunohistochemistry as a method for pre-
dicting HER-2 gene ampliﬁcation status in a series
of patients with IHC HER-2 2+, 3+ breast cancer
and to study associations between HER-2 status
and clinicopathological factors.
MATERIALS AND METHODS
Patients
In this study we enrolled 190 patients diagnosed with
invasive breast cancer including 160 HER-2 2+ and 30
HER-2 3+ in Alzahra hospital of Isfahan from March
2012 to August 2014. All patients were newly conﬁrmed
for invasive breast cancer status and have not received
treatment. The patients and participants signed approved
institutional review board consent forms before inclusion
in the study. Patient clinical history and tumor character-
istics were obtained from histopathology reports and
medical records. Gathered data included age histological
grade, tumor size, regional lymph node status, lymphovas-
cular invasion, estrogen receptor (ER), progesterone recep-
tor (PR), and HER-2 status. Nottingham criteria used to
describe histological grade (18, 19). The tumor extent was
measured by TNM staging according to the new staging
system of the American Joint Committee on Cancer/Inter-
national Union against Cancer (AJCC/UICC) (20). This
study was approved by research and ethics committee of
Isfahan University of medical sciences.
Immunohistochemistry
Human epidermal growth factor receptor-2 IHC stains
were performed with the HercepTest according to the
manufacturer’s instructions: the HercepTest (DAKO,
Glostrup, Denmark). Each IHC stain was run with the kit
control slides according to the manufacturers’ instructions.
Brieﬂy, 4-lm-thick mounted sections on slides from
formaldehyde-ﬁxed paraﬃn-embedded tissue blocks were
deparaﬃnizad by xylene solution for 5 min and rehy-
drated in graded alcohols for 3 min. After deparaﬃniza-
tion, tissue sections were placed in 0.1 M sodium citrate
buﬀer (PH 6) for 40 min at 99 °C, after which the antigen
was retrieved. The slides were then incubated with pre-
diluted anti-HER2 antibody for 1 h. After incubation, the
sections were washed in PBS and incubated with horserad-
ish peroxidase-conjugated secondary antibody. Color
development was performed using 3,30-diaminobenzidine,
and the tissue samples were counterstained with hema-
toxylin. Negative and positive control slides were included
in each assay. Samples were interpreted according to the
ASCO/CAP guidelines: negative (0, 1+), weakly positive
(2+), and strongly positive (3+). The results were inter-
preted by two independent pathologists.
All cases also underwent immunochemistry for hor-
mone receptors. Primary antibodies used were mouse
monoclonal anti-human ER antibody (1D5, Dako,
Glostrup, Denmark) and mouse monoclonal anti-human
progesterone receptor (PgR636, Glostrup, Denmark) anti-
body. A cutoﬀ level of 10% or greater was deﬁned as pos-
itive for ER and PR expression.
FISH
The Cytocell HER-2 probe kit (LPS 001; Aquarius, Cyto-
cell Technologies, Cambridge, UK) was used to analyze
samples by FISH according to the supplier’s instructions.
First, the sections were baked overnight. Following
deparaﬃnization by xylene, the slides were dehydrated
and air-dried. The enzyme was freshly prepared by dilu-
tion. After protease digestion for 18 min, the slides and
probes for HER-2 and the centromere of chromosome 17
(internal control) were treated at 72 °C for 2 min in
denaturation solution simultaneously. The probes and tar-
get DNA were hybridized in a humidiﬁed chamber at
37 °C overnight. The slides were washed with Post-hybri-
dization wash buﬀer by 0.49 SSC at 72 °C for 2 min and
once with 29 SSC at room temperature for 30 seconds
and counterstained with 4,6-diamidino-2-phenylindole.
The number of chromosome 17 and HER-2 signals were
scored for 20 tumor cell nuclei in the invasive tumor
region which had been previously marked by the patholo-
gist. HER-2 gene status was evaluated based on the ratio
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of HER-2 signals and chromosome 17 centromic signals.
A mean CEP17 signals per nucleus of ≥3 was considered
as polysomy 17 (21). The FISH specimens were analyzed
on a Nikon Eclipse 80i ﬂuorescence microscope (Nikon
Corp, Tokyo, Japan) with special ﬁlters. In our study, a
case was regarded HER-2 gene ampliﬁed if the ratio of
HER-2/CEP17 was equal to or more than 2.0 as FDA
recommendation.
Statistical analysis
Pearson’s chi-square test was performed to evaluate the
association between clinicopathological variables and
HER-2 FISH positivity. Student’s t-test was used to com-
pare age between the HER-2 negative and positive groups.
Probability values <5% were considered statistically
signiﬁcant.
For showing inﬂuence of risk factors on HER-2 status
(dependent variable) we used logistic regression model. In
order to choose variables to involve in logistic regression,
variables entered in logistic regression with HER-2 status
one by one and crude OR noted. After that variables with
p value ≤0.2 considered for ﬁnal multivariable logistic
regression model.
All statistical analysis were performed using the PASW
Gradpack 21 (SPSS Inc. Chicago, IL, USA).
RESULTS
This study consisted of 190 invasive breast cancer
patients (160 HER-2 2+ and 30 HER-2 3+). Study
population median age was 48.63 years (range, 27–
77 years). Histhopathological grade was available
In 135 patients (71.0%). 90 patients (47.3%) were
grade 1 or 2 and 45 patients (25.2%) were grade 3.
Hormone receptor (HR) status was available in all
patients. ER was expressed in 141 patients (74.2%).
PR also was expressed in 122 patients (64.2%).
Hundred and twelve patients (58.9%) were ER and
PR positive and 10 patients (5.2%) were ER nega-
tive and PR positive. Lymphovascular invasion
(LVI) was seen in 45.7% (87 patients). The tumor
size (T) and regional lymph node status (N) are
shown in Table 1.
HER-2 FISH ampliﬁcation according to FDA
criteria was found 27.5% (44/160 patients) in HER-
2 2+ patients and 83.3% (25/30 patients) in HER-2
3+ patients. Totally 69 patients (36.3%) were HER-
2 FISH ampliﬁed (Table 1).
No signiﬁcant diﬀerences existed between HER-2
positive and HER-2 negative groups with respect to
age (48.82 years vs 48.52 years, p = 0.854), cancer
location (p = 0.108), lymphovascular invasion
(p = 0.303) or increased chromosome 17 copy num-
ber (p = 0.493). Patients with HER-2 FISH ampliﬁ-
cation tumors were not likely to have higher
histological grades (p = 0.371) compared with
patients with unampliﬁed tumors. Tumors with
HER-2 ampliﬁcation were more likely to be ER-
negative (51.0% vs 31.2%, p = 0.013) and PR-
negative (52.9% vs 27.0%, p < 0.001) (Table 2).
A logistic regression model was used to reveal
risk factors for HER-2 ampliﬁcation. The purpose
of this logistic regression is to discover the impact
of each clinicopathological variable on HER-2
ampliﬁcation singly; considering that other vari-
ables may aﬀect the target variable’s result. The
association between clinicopathological variables
and HER-2 ampliﬁcation is shown in Table 3.
Tumor location, T stage, N stage, ER status, and
PR status entered in ﬁnal logistic regression model.
Subjects with ER-positive expressions were less
likely to exhibit HER-2 ampliﬁcation compared
Table 1. Distribution of HER-2 FISH results in IHC 2+
and 3+ breast cancer patients based on FDA guidelines
FISH negative (%) FISH positive (%) Total
IHC 2+ 116 (72.5) 44 (27.5) 160
3+ 5 (16.7) 25 (83.3) 30
Total 121 (63.7) 69 (36.3) 190
Table 2. correlation of HER-2 FISH results with
clinicopathological variables in 190 breast cancer patients
(signiﬁcant P values are shown bold)
HER-2
negative
n (%)
HER-2
positive
n (%)
p
Patients 121 (63.7) 69 (36.3)
Age 48.82 48.52 0.854
Location
Left 52 (57.8) 38 (42.2) 0.108
Right 69 (69) 31 (31)
Histological grade
1–2 61 (67.8) 29 (32.2) 0.371
3 27 (60) 18 (40)
Not evaluable 33 (60) 22 (40)
T stage
1 25 (71.4) 10 (28.6) 0.224
2 86 (64.7) 47 (35.3)
3 8 (44.4) 10 (55.6)
4 2 (50) 2 (50)
N stage
0 53 (69.7) 23 (30.3) 0.329
1 41 (64) 23 (36)
2 16 (51.6) 15 (48.4)
3 11 (57.9) 8 (42.1)
LVI
Negative 69 (67.0) 34 (33.0) 0.303
Positive 52 (59.8) 35 (40.2)
ER status
Negative 24 (48.9) 25 (51.1) 0.013
Positive 97 (68.7) 44 (31.3)
PR status
Negative 32 (47.2) 36 (52.9) <0.001
Positive 89 (73.0) 33 (27.0)
Polysomy 17
Negative 98 (64.9) 53 (35.1) 0.493
Positive 23 (59.0) 16 (41.0)
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with those with ER-negative expression
(OR = 0.24; 95% CI = 0.07–0.87; p = 0.030). The
risk was also reduced in cases with PR-positive
expressions than those with PR-negative expres-
sions (OR = 0.32; 95% CI = 0.14–0.74; p = 0.008).
There was polysomy 17 in 39 (20.5%) patients of
which 35 (21.8%) and 4 (13.3%) cases were IHC
2+, and IHC 3+ respectively (Table 4).
DISCUSSION
Human epidermal growth factor receptor-2, has been
widely accepted as a prognostic and predictive mar-
ker in the management and treatment of breast can-
cer (22). Using trastuzumab supplement for
neoadjuvant or adjuvant chemotherapy provides sig-
niﬁcant survival beneﬁt in invasive breast cancer with
HER-2-overexpressing tumor cells. However, for
HER-2-negative cases, with any IHC score, trastuzu-
mab oﬀers no beneﬁt and only contributes cardiotox-
icity and waste of money (16, 17). The high cost and
side eﬀects of trastuzumab therapy demand that
highly accurate, robust, sensitive, and cost-eﬀective
testing protocols be used in clinical settings (16, 23).
The best method to evaluate HER-2 status of
breast cancer is still debated among pathologists.
Because each technique has its own advantages and
disadvantages, a standard screening tool has not yet
been determined. Several studies have proposed IHC
as the ﬁrst line screening method for HER-2 status
(15, 24). IHC staining is easy to perform and rela-
tively inexpensive as a method for evaluating HER-2
status. However, there is a wide range of inter- and
intra-laboratory variation in its sensitivity and speci-
ﬁcity (25, 26). Factors such as tissue ﬁxation (and its
impact on HER-2 protein antigenicity), the scoring
method, and the choice of antibody may contribute
to a lower speciﬁcity and sensitivity of IHC (23, 27).
Based on a recent study, false results could be
decreased by standardization of these pre-analytic
steps of IHC (28). Cases with weak positive staining
(2+) by HER-2 IHC represent a subgroup of patients
that requires additional assessment with FISH.
Applying updated ASCO/CAP recommendations
would improve overall accuracy of HER2 testing due
to the widening of IHC 2+ cases (28). Some research-
ers have previously studied the probability of HER-2
2+ IHC breast cancers for HER-2 ampliﬁcation (17).
In a study which was also in Iranian population 36%
of HER-2 2+ samples were HER-2 ampliﬁed (23).
Another study with a relatively large population of
1735 breast cancer HER-2 ampliﬁcation were seen in
14% of patients (29). Other studies have also
reported 30–35% HER-2 ampliﬁcation among IHC
samples 2+ score (30, 31).
Numerous previous studies have reported that
HER-2 overexpression (IHC 3+) or HER-2 ampliﬁ-
cation is associated with high tumor cell grade,
absence of ER or PR expression, DNA aneuploidy,
and high Ki-67 (32, 33). Many studies also investi-
gated factors which could predict HER-2 ampliﬁca-
tion in breast cancer patients. In a study which
assessed correlation of diﬀerent risk factors with
HER-2 ampliﬁcation in IHC 2+ breast cancer
patients, ER and PR positivity were shown to be
related with negative HER-2 status and better
prognosis (17).
In our study, we integrated clinical and patholog-
ical factors from 190 breast cancer cases with IHC
score of 2+ and 3+. All samples were routinely sub-
mitted for FISH analysis to determine the HER-2
gene status. We found that 27.5% (44/160) of IHC
2+ cases were HER-2 ampliﬁed. Which was a lower
percentage in comparison with most of other stud-
ies. The reason is probably the fact that in the new
ASCO/CAP HER2 testing recommendation update
used in this study, the IHC 2+ “equivocal” category
has been expanded to include cases that would have
previously been classiﬁed as 1+ negative or 0 nega-
tive (3). Positive correlation was also found
between HR and HER-2 status agreeing with previ-
ous studies. We expected to see higher tumor size
(T stage) and regional lymph node involvement
Table 3. Logistic regression analysis of risk factors for
HER-2 FISH positive in 190 breast cancer patients (In all
variables, ﬁrst condition is supposed as reference)
(signiﬁcant P values are shown bold)
OR 95% CI p
Age group
(<50, ≥50)
Crude 1.12 0.62–2.02 0.711
Adjusted – – –
Location
(Left, Right)
Crude 0.62 0.34–1.12 0.109
Adjusted 0.76 0.25–2.32 0.639
Histological grade
(1–2, 3)
Crude 1.40 0.67–2.95 0.372
Adjusted – – –
T stage
(T1, T2-3-4)
Crude 1.58 0.95–2.62 0.072
Adjusted 1.63 0.96–2.77 0.067
N stage
(N0, N1-2-3)
Crude 1.28 0.94–1.72 0.107
Adjusted 0.64 0.32–1.28 0.215
LVI
(negative, positive)
Crude 1.37 0.76–2.47 0.303
Adjusted – – –
ER status
(negative, positive)
Crude 0.44 0.22–0.85 0.014
Adjusted 0.24 0.07–0.87 0.030
PR status
(negative, positive)
Crude 0.33 0.18–0.61 <0.001
Adjusted 0.32 0.14–0.74 0.008
Table 4. HER-2 gene ampliﬁcation in IHC 2+ and 3+
breast cancer patients with Polysomy 17 (mean CEP17
signals per nucleus of ≥3)
FISH negative (%) FISH positive (%) Total
IHC 2+ 22 (62.9) 13 (37.1) 35
3+ 1 (25) 3 (75) 4
Total 23 (59.0) 16 (41.0) 39
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(N stage) in HER-2-ampliﬁed patients, but they did
not have signiﬁcant association. However, T stage
was very close to have a relation with HER-2 posi-
tivity based on our results (p = 0.067). Higher
tumor grade and lymph node invasion also had no
association with HER-2 ampliﬁcation. We also
found ﬁve cases with IHC 3+ score to be HER-2
negative on FISH. Based on established literature
data it can be assumed that the way and duration
of antigen retrieval and ﬁxation can lead to incon-
sistent and incorrect IHC results (34). FISH assay
is less prone to ﬁxation and laboratory errors than
IHC tests, making FISH assay more reproducible if
signal interpretation is carried out by experienced
pathologists. However, many studies stated that
HER-2 IHC false positive cases still beneﬁt from
adjuvant trastuzumab therapy (35).
Polysomy 17 is common among invasive breast
cancer patients, however, the exact eﬀect of polys-
omy 17 on HER-2 ampliﬁcation remains controver-
sial (21). Some studies have reported that breast
cancer patients with polysomy 17 respond to trastu-
zumab therapy independently of HER-2 ampliﬁca-
tion (36), however, other researchers believe that
polysomy 17 patients without HER-2 ampliﬁcation
do not beneﬁt from anti HER-2 agents (13). Preva-
lence of polysomy 17 is reported in the range of 3–
46% using the deﬁnition of ≥3 CEP per cell (37). In
this study polysomy 17 was seen in 20.5% of
patients. Also polysomy 17 is reported to be more
common in IHC 2+ cases which agrees the ﬁndings
of our study (38).
Some limitations were observed in this study.
First we did not include Ki-67 and p-53 in breast
cancer risk factors while many studies did show
that they can predict HER-2 status. The other limi-
tation was few numbers of patients, especially IHC
3+ cases which was due to the FDA criteria to per-
form FISH for IHC 2+ patients only. Our IHC 3+
cases which FISH was performed for them were
those who had a relative contraindication for Her-
ceptin therapy like patients with high blood pres-
sure or heart failure; Therefore these patients may
not be representative of IHC +3 patients in general.
In a recently meta-analysis, HER-2 IHC 0/1+ and
3+ cannot be absolutely considered as negative and
positive (39). In our study results also 16.7% (5/30)
of patients with 3+ IHC score were not HER-2
ampliﬁed which conﬁrmed this fact.
In conclusion, IHC can not be the best method
for evaluating HER-2 ampliﬁcation in breast cancer
patients even in patients with 3+ score. Studying
alternative methods for detecting HER-2 ampliﬁca-
tion should be considered. Researches with larger
groups and more predicting risk factors must per-
form in diﬀerent populations.
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